KD: 300 nM (apelin receptor in CHO-K1 cells), 172 nM (apelin receptor in human heart)[1].
In Vivo
MM 07 causes a dose-dependent increase in cardiac output, and although there is a decrease in vascular resistance, this is without corresponding effects on BP. Administration of SNAP produces a profound fall in BP in both [Pyr1]apelin-13 and MM 07-treated groups; however, although cardiac output is significantly increased in response to SNAP in the MM 07 group, it is significantly reduced in the [Pyr1]apelin-13 group. Neither peptide causes a significant change in heart rate, respiratory rate, or temperature. Both [Pyr1]apelin 13 and MM 07 increases peak velocity above basal levels[1].
In Vitro
MM 07 competes with nanomolar affinities for binding of [Glp65,Nle75,Tyr77] [125I]apelin-13 to human apelin receptors in CHO-K1 cells (KD, 300 nM) and human heart (KD, 172 nM, n=3)[1].
Kinase Assay
Cell Assay
Animal Administration
Rats[1]Rats (230-260 g), anaesthetized with 2% isoflurane, are given a single intravenous bolus (600 nM) of apelin or MM 07 (both n=3)[1].
References
[1]. Brame AL, et al. Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension. 2015 Apr;65(4):834-40.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.